Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (241-250 of 343) with videos related to

Pageof 35
Sort By:
Blood|February 26, 2017
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemiaLian Xu, Nicholas Tsakmaklis, Guang Yang, et al.
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Hemasphere|July 11, 2020
Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical TrialsJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Annals of Hematology|August 3, 2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyArtur Jurczyszyn, Alessandro Gozzetti, Joanna Gdula-Argasińska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2018
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström MacroglobulinemiaSteven P Treon, Joshua Gustine, Kirsten Meid, et al.
Blood Advances|September 9, 2025
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN studyRamón García-Sanz, Roger G Owen, Wojciech Jurczak, et al.
British Journal of Haematology|March 13, 2018
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphomaJorge J Castillo, Thomas Guerrero-Garcia, Francesco Baldini, et al.
Blood|June 16, 2016
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Guang Yang, et al.
Blood Advances|January 16, 2026
Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom MacroglobulinemiaNickolas Tsakmaklis, Zachary R Hunter, Xia Liu, et al.
Blood Advances|December 29, 2021
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapyJorge J Castillo, Shayna R Sarosiek, Joshua N Gustine, et al.
Pageof 35

Showing results (241-250 of 343) with videos related to

Sort By:
Pageof 35
Blood|February 26, 2017
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemiaLian Xu, Nicholas Tsakmaklis, Guang Yang, et al.
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Hemasphere|July 11, 2020
Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical TrialsJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Annals of Hematology|August 3, 2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyArtur Jurczyszyn, Alessandro Gozzetti, Joanna Gdula-Argasińska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2018
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström MacroglobulinemiaSteven P Treon, Joshua Gustine, Kirsten Meid, et al.
Blood Advances|September 9, 2025
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN studyRamón García-Sanz, Roger G Owen, Wojciech Jurczak, et al.
British Journal of Haematology|March 13, 2018
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphomaJorge J Castillo, Thomas Guerrero-Garcia, Francesco Baldini, et al.
Blood|June 16, 2016
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Guang Yang, et al.
Blood Advances|January 16, 2026
Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom MacroglobulinemiaNickolas Tsakmaklis, Zachary R Hunter, Xia Liu, et al.
Blood Advances|December 29, 2021
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapyJorge J Castillo, Shayna R Sarosiek, Joshua N Gustine, et al.
Pageof 35